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Revisiting adult neurogenesis and the role of erythropoietin
for neuronal and oligodendroglial differentiation in the
hippocampus
I Hassouna1,14,15, C Ott1,15, L Wüstefeld1,15, N Offen2, RA Neher3, M Mitkovski4, D Winkler1, S Sperling1, L Fries2, S Goebbels5, IC Vreja6,7,
N Hagemeyer1, M Dittrich8, MF Rossetti1, K Kröhnert6, K Hannke1, S Boretius9, A Zeug10, C Höschen11, T Dandekar8, E Dere1,
E Neher12,13, SO Rizzoli6,13, K-A Nave5,13, A-L Sirén2 and H Ehrenreich1,13
Recombinant human erythropoietin (EPO) improves cognitive performance in neuropsychiatric diseases ranging from
schizophrenia and multiple sclerosis to major depression and bipolar disease. This consistent EPO effect on cognition is
independent of its role in hematopoiesis. The cellular mechanisms of action in brain, however, have remained unclear. Here we
studied healthy young mice and observed that 3-week EPO administration was associated with an increased number of pyramidal
neurons and oligodendrocytes in the hippocampus of ~ 20%. Under constant cognitive challenge, neuron numbers remained
elevated until 46 months of age. Surprisingly, this increase occurred in absence of altered cell proliferation or apoptosis. After
feeding a 15N-leucine diet, we used nanoscopic secondary ion mass spectrometry, and found that in EPO-treated mice, an
equivalent number of neurons was deﬁned by elevated 15N-leucine incorporation. In EPO-treated NG2-Cre-ERT2 mice, we
conﬁrmed enhanced differentiation of preexisting oligodendrocyte precursors in the absence of elevated DNA synthesis. A
corresponding analysis of the neuronal lineage awaits the identiﬁcation of suitable neuronal markers. In cultured neurospheres,
EPO reduced Sox9 and stimulated miR124, associated with advanced neuronal differentiation. We are discussing a resulting
working model in which EPO drives the differentiation of non-dividing precursors in both (NG2+) oligodendroglial and neuronal
lineages. As endogenous EPO expression is induced by brain injury, such a mechanism of adult neurogenesis may be relevant for
central nervous system regeneration.
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INTRODUCTION
Erythropoietin (EPO) and its receptor, EPOR, were originally named
because of their pivotal contribution to hematopoiesis, but over
the last ~ 20 years, their important role also in the nervous system
became more and more evident.1–2 EPO and EPOR expression in
normal postnatal brain is low3 but distinct in areas like
hippocampus and cortex.4–5 Strong upregulation is observed
upon distress, for example, brain injury.2,6 In healthy rodents and
man, recombinant human EPO improves cognition and increases
hippocampal long-term potentiation.7,8 Beneﬁcial effects of EPO
on cognitive performance were consistently seen in clinical trials
on schizophrenia, multiple sclerosis, major depression or bipolar
disease, for example, see refs 9–13. Importantly, these EPO actions
on the brain are essentially independent of hematopoiesis. There
was either no increase in hematocrit or no correlation between
such increase and cognition in these clinical trials. Moreover, the
effect on cognition by far outlasted any transient effect on
hematocrit, for example, see refs 9–13. Even more convincingly,
non-hematopoietic EPO analogs14 or the boosted cognition of
mice with expression of constitutively active EPOR in pyramidal
neurons15 are key arguments for brain effects of EPO in the
absence of any blood effects.
Nevertheless, the exact mechanisms of EPO action in brain have
still remained widely unclear. Some of the neuroprotective and
neuroregenerative effects of EPO in disease models were
speculated to be associated with stimulation of neurogenesis,
for example, see refs 16–19, but essentially no data are available to
clearly support this hypothesis or to discriminate between EPO
effects on neural progenitor proliferation versus differentiation
in postnatal brain.17 In the hematopoietic system, EPO is crucial
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for antiapoptotic effects on erythroid precursors and for their
differentiation rather than for proliferation.20 We therefore
wondered whether similar mechanisms may also apply for the
nervous system.
Adult neurogenesis has been discovered by labeling mitotic
cells of the brain with 5’-bromo-deoxyuridine (BrdU) or
3H-thymidine incorporation into nuclear DNA. This led to the
identiﬁcation of restricted neurogenesis areas in the adult brain,
mainly dentate gyrus (DG) and subventricular zone (SVZ).21–25 For
oligodendrocytes, the situation is different, as adult precursor cells
(OPC) are widely distributed throughout the central nervous
system.26 Adult OPC are multipolar cells, morphologically distinct
from small and rapidly dividing progenitors in the SVZ and
molecularly deﬁned by speciﬁc antigens, such as platelet-derived
growth factor receptor α (PDGFRα) and the proteoglycan
NG2.27–30
Based on our ﬁndings of EPO enhancing cognition and long-
term potentiation,7 and the popular concept of neurogenesis
leading to more neurons and more neurons to better learning and
memory,22,31–33 we initiated the present work. We report here the
surprising ﬁnding that (1) only 3-week administration of EPO to
healthy young mice is associated with an approximately 20%
increase in the number of mature neurons and oligodendrocytes
in hippocampal cornu ammonis (CA1/CA3); (2) under enduring
cognitive challenge, these neuron numbers are preserved; (3) this
EPO effect involves stimulation of precursor differentiation rather
than proliferation or anti-apoptosis. We discuss a resulting
working model, in which these observations are—beyond EPO
—compatible with a new aspect of postnatal neurogenesis and
neuroregeneration.
MATERIALS AND METHODS
Important note: All experiments in this article, including histological
counting, were performed by investigators unaware of (i) group assign-
ment and (ii) treatments ('fully blinded’).
In vivo studies
An overview of in vivo studies performed is given in Figure 1a.
Mice
All experiments were approved by and conducted in accordance with the
regulations of the local Animal Care and Use Committee (Niedersäch-
sisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit—
LAVES). Juvenile (28-day-old) male C57BL/6 mice as well as NG2-Cre-ERT2:
R26R-td-tomato-mEGFP34,35 mice on C57BL/6 background were used in all
experiments. They were housed in groups of ﬁve in standard plastic cages
and maintained in a temperature-controlled environment (21 ± 2 °C) on a
12 h light–dark cycle with food and water available ad libitum. Mice were
always randomly assigned to treatment groups. Inclusion–exclusion criteria
were pre-established. Included were only male mice with same age and
similar body weight. Exclusion criteria before experiment start were
impaired health or body weight lower than average. No animals had to be
excluded during any of the experiments. Criteria to exclude mice from
statistical analysis were determined by the Grubbs’ test using GraphPad
Software (graphpad.com/quickcalcs). Genotyping of Cre driver and
reporter lines have been described.34,35 Detailed PCR protocols are
available on request.
EPO treatment
Male mice were injected intraperitoneally (i.p.) with recombinant human
EPO (NeoRecormon, Roche, Welwyn Garden City, UK, 5000 IU kg–1 body
weight in 0.01 ml g–1) or placebo (solvent solution, 0.01 ml g–1). Treatment
was started at the age of 28 days. Depending on the experiment, EPO was
given once (early time point of 6 h) or every other day (later time points of
72 h, 1 week or 3 weeks). BrdU was injected i.p. daily for 3 weeks (5-bromo-
2'-deoxyuridin, Sigma-Aldrich, Taufkirchen, Germany, 50 μg g–1 in 0.01ml
saline).36 For induction of Cre-activity in NG2-Cre-ERT2 mice, 100 mg kg–1
tamoxifen (in corn oil; Sigma-Aldrich) was injected i.p. at P26 and P27.
Cognitive challenge: touch-screen visual discrimination task
Mice. Male 4-week-old C57BL/6 mice received either EPO (n=10) or
placebo (n= 11) i.p. every other day over 3 weeks (11 injections in total).
After the last injection, the animals were adapted for 1 week to the food
deprivation procedure (85% of free feeding body weight) before start of
the touch-screen experiment.
Touch-screen-based operant system. Experimental procedures and visual
stimuli were based on a previous publication37 with slight modiﬁcations.
The operant chamber (dimensions: 18.1 cm×17.6 cm×18.6 cm), enclosed
in a sound and light attenuating box (Med Associates, St Albans, VT, USA),
contained a pellet dispenser, which delivered a single 14 mg dustless
pellet (TSE Systems, Bad Homburg, Germany) into a food tray (magazine).
A touch-sensitive TFT monitor (touch-screen; 18.4 cm×13.6 cm) was
located on the opposite side of the chamber. The touch-screen was
divided into two parts, allowing two different visual stimuli (of maximally
7.5 cm×7.5 cm each) to be presented simultaneously (Controller Software,
K-Limbic, Sawbridgeworth, UK).
Touch-screen experimental procedures. Mice were tested on 6 consecutive
days per week. Every mouse underwent the following sequence of test
phases: (1) acclimation, (2) autoshaping, (3) pre-training 1–3 and (4) visual
discrimination. The daily sessions were terminated after 30 min or when
the mouse had accomplished the speciﬁc learning criterion of the
respective test phase.
Acclimation: Pellets were freely available in the magazine (prime
reward) with an inter-trial interval of 15 s. A new trial was initiated after
collection of the pellet leading to a disruption of an infrared light beam.
This test phase was completed after the animal had collected 10 pellets
within 30 min.
Autoshaping: The session started with a three pellets prime reward.
After the mouse had collected the pellets, two identical stimuli were
presented on both sides of the touch-screen for 10 s. The disappearance of
the stimuli coincided with a tone, illumination of the pellet tray and the
delivery of one pellet. A new trial was initiated after collection of the pellet
(inter-trial interval 15 s). Animals that collected 30 pellets within 30 min
moved on to the pre-training phase.
Pre-training 1: Again the session started with a three pellets prime
reward. After the mouse had collected the pellets, one stimulus was
presented pseudo-randomly on the left or right side of the touch-screen. A
touch response to the correct side where the stimulus was presented
activated the pellet dispenser to release a pellet into the magazine, which
was illuminated and signaled by a tone (inter-trial interval 5 s). This test
phase was completed after the animal had performed 30 correct responses
within 30 min.
Pre-training 2: This test phase was identical to pre-training 1 except
that the mouse had to actively initiate a new trial by disrupting the infrared
light beam in the magazine a second time (after it had collected the food
pellet). Only then the next stimulus could appear.
Pre-training 3: This test phase was identical to pre-training 2 except
that an incorrect response to the blank side of the touch-screen where no
stimulus was presented resulted in a 5 s timeout with house light turned
off and the initiation of a correction trial (maximum of four possibilities to
correct the faulty response) with the same stimulus conﬁguration
presented. This test phase was completed after the mouse had performed
at least 27 correct responses out of 30 trials.
Visual discrimination: This test phase was identical to pre-training 3
except that two different stimuli S+ and S– were presented simultaneously
and in a pseudorandom order on the left and right side of the touch-
screen. The selection of the stimulus S+ (correct response) led to the
disappearance of both stimuli, presentation of a tone, illumination of the
food magazine, delivery of a pellet. A new trial could be initiated after the
collection of the pellet and an inter-trial interval of 5 s. The selection of the
stimulus S– (incorrect response) resulted in a 5 s timeout with house light
turned off and the initiation of a correction trial (maximum of four
possibilities to correct the faulty response) with the same stimulus
conﬁguration presented. The test phase was completed if the mouse
accomplished 27 correct responses out of 30 trials or 26 correct responses
out of 30 trials on 2 consecutive days, whichever appeared ﬁrst (correction
trials not counted). The experiment was concluded for a given mouse after
it had been tested for 61 days including all four test phases.
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Figure 1. Erythropoietin (EPO) effects on neuron number, proliferation and apoptosis in CA1 and CA3. All data are based on bilateral counting.
(a) Experimental design of the in vivo experiments (see f for age at treatment in the magnetic resonance imaging (MRI) design). Mice received
EPO or placebo intraperitoneally (i.p.) every other day, starting on postnatal day 28. (b) Number of pyramidal neurons in CA1 and CA3 at
1 week after 3-week EPO versus placebo treatment (w4) (analysis was performed in two independent experiments with identical results; n= 17
in CA1 for both groups, and n= 16 and n= 18 in CA3 for placebo and EPO, respectively). (c) Sample cresyl violet staining, illustrating that
pyramidal neurons (arrowhead) can be clearly distinguished from other cells (arrow). (d) Number of CTIP2+ pyramidal neurons in CA1 at w4
(n= 4 per group). (e) Illustration of the CTIP2 staining in the dorsal hippocampus. The white rectangle indicates the magniﬁed area shown in
the lower right corner. (f) MRI-based volumetrical analysis of whole hippocampus (HC) after EPO or placebo (n= 6 per group; treatment in this
set of male mice was initiated at 11 weeks of age; that is, MRI data were obtained at age 15 weeks). (g) Proliferation determined by 5’-bromo-
deoxyuridine (BrdU) incorporation at w4 (placebo n= 7 and EPO n= 6). (h) Apoptotic cells analyzed with terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (Tunel) staining at w4 (n= 10 for both groups). (i) Confocal analysis of BrdU and NeuN double-
positive cells at w4 (n= 6 for both groups). (j) Confocal picture showing a neuron staining positively for NeuN (green) and BrdU (red). (k and l)
Number of Pax6-positive cells at 72h and w1 (n= 9 per group). (m) Pax6+ cells (arrows) visualized by 3,3’-diaminobenzidine (DAB) staining. (n)
Number of doublecortin (Dcx)-positive cells at w4 (n= 9 per group). (o) Sample picture of Dcx+ cells. All bar graphs shown as mean± s.e.m.; all
analyses unpaired, two-tailed t-tests; *Po0.05, **Po0.01, *** Po0.001, ****Po0.0001.
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Hippocampus volumetry using magnetic resonance imaging (MRI)
Male mice at the age of 15 weeks (1 week after 3 weeks of EPO treatment, that
is, 4 weeks after EPO treatment start at 11 weeks of age) were anesthetized
with 1–1.5% isoﬂurane in a mixture of oxygen and ambient air and positive
ventilated via endotracheal tube. For in vivo volumetry,38 three-dimensional
fast low angle shot (FLASH; TR/TE=14.9/3.9 ms) MRI was performed at 9.4T
(Bruker Biospin, Rheinstetten, Germany) with an isotropic spatial resolution of
110 μm. Hippocampal volume was determined by manual segmentation
using the Amira software (Visage Imaging GmbH, Berlin, Germany).
Histology and immunohistochemistry
Mice were anesthetized by i.p. injection with Avertin (Tribromoethanol,
Sigma-Aldrich, St Louis, MN, USA, 0.276 mg g–1) and perfused transcardially
with 0.9% saline followed by 4% paraformaldehyde (PFA). Brains were
removed, postﬁxed overnight at 4 °C with 4% PFA and placed in 30%
sucrose/phosphate-buffered saline (PBS) for cryoprotection and stored at
-80 ˚C. Whole mouse brains were cut into 30 μm thick coronal sections on
a cryostat (Leica, Wetzlar, Germany) and kept in a storage solution (25%
ethylene glycol and 25% glycerol in PBS) at –20 °C.
Cresyl violet staining. Every 10th section was mounted on Super Frost
microscopic slides (Gerhard Menzel B.V. & Co. KG, Braunschweig, Germany),
washed in PBS and immersed for 25 min in dilute cresyl violet stain (0.01%) in
acetate buffer (pH 4.5). After dehydration in serial dilutions of ethyl alcohol,
sections were coverslipped using DePeX (Serva, Heidelberg, Germany).
Pax6, Dcx, Olig1, PDGFRα, BrdU, Ki67 staining. Every 4th section for BrdU,
every 8th for Ki67, every 10th section for Dcx, PDGFRα and Olig1, and every
20th section for Pax6 were washed three times with PBS and mounted on
Super Frost microscopic slides. They were dried overnight and rehydrated
in PBS. Sections for Pax6, Dcx, Ki67, PDGFRα and Olig1 were microwaved
three times for 2 min in citrate buffer. For BrdU staining, sections were
pretreated with 1N HCl for 30 min at room temperature (RT). All sections
were incubated with 0.5% hydrogen peroxide for 30 min to quench
endogenous peroxidases. Afterward, they were permeabilized and blocked
with 5% normal horse serum (NHS), 0.5% Triton-X in PBS for 1h at RT. The
following primary antibodies (ﬁnal dilution and source) were used for
tissue staining: rabbit anti-Pax6 (1:200, Chemicon, Hampshire, UK), goat
anti-Dcx (1:750, Santa Cruz Biotechnologies, Heidelberg, Germany), rabbit
anti-PDGFRα (1:2000, Cell Signaling, Danvers, MA, USA), rabbit anti-Olig1
(1:100, Chemicon), mouse anti-BrdU (1:4000, Chemicon) and rabbit
anti-Ki67 (1:1000, Novocastra Laboratories, Newcastle Upon Tyne, UK).
Antibodies were diluted in 3% NHS, 0.5% Triton-X in PBS. After washing
with PBS, sections were incubated with the respective biotinylated
secondary antibody for 1.5 h (1:200, Vector Laboratories, Burlingame, CA,
USA). The staining was visualized by a peroxidase-labeled avidin-biotin kit
(Vector Laboratories) and 3,3’-diaminobenzidine (Sigma-Aldrich). Sections
were allowed to dry overnight and coverslipped using DePeX (Serva).
TUNEL staining. To detect cells undergoing apoptosis, an in situ detection
kit (DeadEnd Colorimetric TUNEL Kit Promega, Mannheim, Germany) was
used. For terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) staining, every 10th section was washed with PBS and
mounted on Super Frost microscopic slides. The staining was performed
according to the manufacturer’s protocol.
Immunoﬂuorescence double staining. For BrdU and NeuN, every 20th
section was washed with PBS and incubated with 1N HCL for 30 min at
45 °C in a shaking water bath. Afterward, sections were permeabilized and
blocked with 5% NHS for 1h at RT. Sections were incubated with mouse
anti-NeuN (1:25, Chemicon) in 3% NHS, 0.5% Triton-X in PBS for 48 h at
4 °C. After washing with PBS, sections were incubated with a ﬂuorescently
labeled secondary antibody (1:1000 goat anti-mouse Alexa Fluor 488;
Invitrogen, Darmstadt, Germany) for 1.5 h at RT. Sections were then
washed and incubated with the direct-labeled mouse anti-BrdU Alexa
Fluor 594 (1:500, Invitrogen) in 3% NHS, 0.5% Triton-X in PBS for 48 h at
4 °C. After washing in PBS, sections were mounted on Super Frost
microscopic slides, dried and coverslipped, using Vectashield HardSet
mounting medium containing 4,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories). For BrdU and Olig1, every 20th section was washed with PBS
and mounted on Super Frost microscopic slides. They were dried overnight
and rehydrated in PBS. Sections were pretreated with 1N HCl for 30min at
RT. Sections were then boiled in citrate buffer, permeabilized and blocked
with 5% NHS for 1h at RT. Sections were incubated with rabbit anti-Olig1
(1:25, Chemicon) and mouse anti-BrdU (1:500, Chemicon) in 3% NHS, 0.5%
Triton-X in PBS for 72 h at 4 °C. After washing with PBS, sections were
incubated with a ﬂuorescently labeled secondary antibody (1:200 anti-
mouse Alexa Fluor 568 Invitrogen,) and anti-rabbit biotinylated (1:200,
Vector Laboratories) for 1.5 h at RT. After washing, sections were incubated
with streptavidin Alexa 488 (1:200, Invitrogen), washed in PBS and
mounted. For green ﬂuorescent protein (GFP) and CC-1, every 10th section
was washed with PBS and mounted on Super Frost slides. They were
allowed to dry overnight and rehydrated in PBS. The sections were
microwaved three times for 2 min in citrate buffer, then permeabilized and
blocked with 5% NHS, 0.5% Triton-X in PBS for 1 h at RT. The following
primary antibodies (ﬁnal dilution and source) were used for tissue staining:
rabbit anti-GFP (1:500, SYSY, Göttingen, Germany), mouse anti-APC, clone
CC-1 (1:100, Merck, Darmstadt, Germany). Antibodies were diluted in 3%
NHS, 0.5% Triton-X in PBS. After washing with PBS, sections were incubated
with horse anti-mouse biotinylated secondary antibody for 1.5 h (1:200,
Vector Laboratories). Staining was visualized by goat anti-rabbit-Cy2
secondary antibody (1:250, Dianova, Hamburg, Germany) and streptavidin
conjugated to Alexa633 (1:250, Life Technologies, Darmstadt, Germany).
After washing, sections were incubated with DAPI in PBS (0.125 μg ml–1,
406 nm; Sigma-Aldrich), dried overnight and coverslipped by Aqua Poly/
Mount (Polysciences, Warrington, PA, USA). For EPOR/GFP double labeling
and CTIP2 stainings, sections (for CTIP2 every 10th) were washed with PBS
and then permeabilized/blocked with 5% NHS, 0.5% Triton-X in PBS for 1 h
at RT on a shaker. As primary antibodies, goat anti-GFP (1:500, Rockland,
Limerick, PA, USA), rabbit anti-EPOR6 and guinea pig anti-CTIP2 (both 1:300,
SYSY) were used. Antibodies were diluted in 3% NHS, 0.5% Triton-X in PBS
and sections incubated with primary antibodies for 72 h at 4 °C on a shaker.
After washing with PBS, sections were incubated with ﬂuorescently labeled
secondary antibodies (donkey anti-goat Alexa Fluor 488 and donkey anti-
rabbit Alexa Fluor 594, both 1:250, Life Technologies, or donkey anti-guinea-
pig-Cy3, 1:300, Dianova) for 1.5 h at RT on a shaker. After washing, sections
were incubated with DAPI in ddH2O (0.125 μg ml
–1, 406 nm; Sigma-Aldrich),
dried overnight and coverslipped by Aqua Poly/Mount (Polysciences).
Histological cell counting
Stereological counting of cresyl violet, Dcx, Ki67, PDGFRα, Olig1, BrdU and
Tunel-positive cells. Serial coronal sections, spaced at regular intervals for
the speciﬁc marker under investigation, were taken through the dorsal
hippocampus (coordinates from Bregma: − 1.34 to − 2.54 mm posterior)
and the SVZ (coordinates from Bregma: 1.18 to − 0.1 mm) for quantitative
analysis. Stereological determination of the cell number was carried out
using the optical fractionator technique (Stereo Investigator, MicroBright-
ﬁeld, Magdeburg, Germany). Cells were counted using a light microscope
(Olympus BX-50, Tokyo, Japan) modiﬁed for stereology with 40x and 100x
oil immersion objectives, a computer-driven motorized stage, z axis
position encoder (microcator), and a microﬁre video camera interfaced to a
PC with the software Stereo Investigator 6.55 (MicroBrightﬁeld, Inc.,
Williston, VT, USA). Cell numbers were estimated using the modiﬁed
optical fractionator technique.39 All stereological analyses for cell counting
were performed on both sides of the hippocampus and SVZ. Hippocampus
CA2/CA3 region is referred to as CA3 in text and ﬁgures. Neurons
were counted only in the pyramidal layers of CA1 and CA3 regions
(Supplementary Figure 1 and Supplementary Table 1). From area
determination of hippocampal subﬁelds, it was estimated that systematic
uniform spacing of random sampling site (SURS grid size, x- and y-steps) of
80×80 μm would provide 410.000 sampling sites if all sections were
analyzed. Accordingly, the x and y dimensions of the counting frame was
deﬁned to be 20×20 μm, giving an average number of particles counted
per optical dissector (with a height of 20 μm and a guard zone of 2 μm from
top and bottom) of about 1–2. The estimated total number of neurons
in CA1 or CA3 was thus the sum of the counted particles multiplied by the
fraction factors 1/ssf, 1/asf and 1/hsf (ssf = section sampling fraction,
asf= area sampling fraction, tsf = thickness sampling fraction; Supplemen-
tary Figure 1 and Supplementary Table 1). Optimizing the sampling scheme
to counting more neurons yielded more precision and a lower coefﬁcient of
error.39 For all markers counted, the same inclusion and exclusion criteria
were applied. The stereological sampling scheme was considered adequate
when coefﬁcient of error was o0.10.40 As this was not the case for Pax6+
cells, because of the relatively low numbers, conventional counting was
applied. Pax6+ cells were counted in CA1 and CA3 regions on serial coronal
sections through the dorsal hippocampus, using a light microscope (Zeiss
Axiostar Plus, Jena, Germany) with 20x and 40x objectives. The counts
represent the mean of CA1 or CA3 counts from four sections per animal.
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Confocal counting of BrdU+/NeuN+, BrdU+/Olig1+, GFP+/CC-1+ and CTIP2+
cells. Confocal laser scanning microscopy (Leica TCS SP2-AOBS for BrdU
+/NeuN+, BrdU+/Olig1+ and Leica TCS SP5-II for GFP+/CC-1+ and CTIP2+)
was used to count ﬂuorescently double-labeled cells in anatomically
matched sections. Every 10th section obtained from the dorsal part of
hippocampus (Bregma –1.34 to –2.54 mm posterior) was analyzed
bilaterally in each animal. All BrdU-positive cells in hippocampal formations
(DG, CA1 and CA3) were examined for either NeuN or Olig1 co-labeling, the
markers for mature neurons and oligodendrocytes respectively. Colocaliza-
tion was conﬁrmed with a z-stack of the respective cell soma, which was
acquired with a line-based sequential scan using 3 μm intervals. The
immunoﬂuorescent double-labeled cells were veriﬁed using oil immersion
63x objective lens. The volume of hippocampal regions was determined
for each section using Cavalieri’s principle.39 Cell density was obtained by
dividing the number of double-labeled cells (BrdU+/NeuN+ or BrdU+/Olig1
+) per animal by the total volume of hippocampal region in mm3. All
GFP+ cells and CTIP2+ in all hippocampus sections were examined for
double labeling with CC-1 and DAPI or CTIP2 and DAPI, respectively.
Colocalization was conﬁrmed with a z-stack of whole hippocampus
sections, which was acquired with a line-based sequential scan, using
0.25-μm intervals and a 20 × glycerol objective. Stacks were further
processed by Fiji (http://ﬁji.sc/Fiji). The ﬁnal quantiﬁcation of GFP+/DAPI+,
CC-1+/DAPI+, GFP+/CC-1+/DAPI+ and CTIP2+/DAPI+ cells was done using
Imaris 7.5.1 (www.bitplane.com).
NanoSIMS experiment
Beginning on postnatal day 28, mice received freely available food pellets
containing 1.025% L-Leucine-15N stable isotope (Sigma-Aldrich, Schnell-
dorf, Germany). On day 28, EPO or placebo treatment was started
according to our standard protocol, with injections every other day for
3 weeks. During this treatment, animals received drinking water containing
0.2 mg ml–1 5-ethynyl-2'-deoxyuridine (EdU, Life Technologies, Eugene, OR,
USA). EPO/placebo treatment, EdU and L-Leucine-15N feeding were
stopped simultaneously. One week later, mice were anesthetized by i.p.
injection with Avertin (Tribromoethanol, Sigma-Aldrich, St Louis, MN, USA,
0.276 mg g–1) and perfused transcardially with 0.9% saline followed by 4%
PFA. Brains were removed, postﬁxed overnight at 4 °C with 4% PFA and
placed in 30% sucrose/PBS for cryoprotection and stored at − 80 °C. Whole
mouse brains were cut into 30 μm thick coronal sections on a cryostat
(Leica) and kept in a storage solution (25% ethylene glycol and 25%
glycerol in PBS) at − 20 °C. Slices of the dorsal hippocampus were
immunostained for NeuN to identify neuronal cell bodies. Furthermore,
EdU detection was accomplished with a Click-iT EdU Alexa Fluorophore
647 Imaging Kit (Life Technologies, Eugene, OR, USA) to label cells
proliferating during the EPO/placebo treatment. In brief, after blocking in
5% NHS, sections were incubated with mouse anti-NeuN (1:500, Chemicon)
for 48 h at 4 °C. After washing with PBS, sections were incubated with a
Cy3-labeled secondary antibody (1:100 goat anti-mouse, Dianova) for 1.5 h
at RT. Sections were washed, permeabilized again and incubated with
Click-iT reaction mix according to the manufacturer’s instruction. The slices
were embedded in LR White resin as previously described,41 and regions
from the CA1 pyramidal layer area were excised and processed to 500 nm
thick sections using a Leica UC6 microtome (Leica). The sections were put
on silicon wafers, and ﬁrst imaged by ﬂuorescence microscopy, to identify
the NeuN-labeled areas. Fiducial markers were imprinted on the sections
using a two-photon laser at 100% power output, to enable the
identiﬁcation of the same areas in the nanoscopic secondary ion mass
spectrometry (NanoSIMS) instrument. Fluorescence imaging was per-
formed using a TCS STED microscope (Leica Microsystems, Wetzlar,
Germany), as described.41 Only areas that did not contain any EdU staining
were used, to exclude the analysis of dividing cells. The silicon wafers were
then mounted in a NanoSIMS 50L device (Cameca, Gennevilliers, France),
and were scanned using Cs+ primary beam. Secondary ions, including
12C14N- and 12C15N-, were detected by mass separation, using a double
focalization mass spectrometer (based on 'Mattauch-Herzog' geometry).
Areas of 39 by 39 μm were imaged, onto 256× 256 pixel rasters, using a
10 ms pixel dwell-time. Several planes (10–40) were acquired repeatedly,
and were assembled into average images using a self-written routine in
Matlab (The Mathworks, Ismaning, Germany). For simplicity, the 12C14N-
and 12C15N- ionic species are referred to as 14N and 15N throughout
the work.
In vitro studies
Design overviews of in vitro studies are given in Supplementary Figures
4A, C and 5A.
Randomization and exclusion criteria
Samples/dishes per wells were randomly assigned to treatment groups.
Exclusion criteria for all experiments were pre-established. Criteria to
exclude cultures from statistical analysis were determined by the Grubbs’
test using GraphPad Software (graphpad.com/quickcalcs).
Neural stem cell (NSC) isolation and culture
NSC were isolated from embryonic mice on day 14 (E14) as described
previously42 with minor modiﬁcations. Whole mouse brains were
mechanically dissociated and cultured in NSC medium (Dulbecco’s
modiﬁed Eagle’s medium/F12 with 15 mM heparin, 2 mM L-glutamine, 2%
B27, 0.22% sodium bicarbonate; all from Invitrogen), 1% penicillin/
streptomycin (PAA, Cölbe, Germany), 0.6% glucose (Sigma-Aldrich), and
supplemented with 20 ng ml–1 human epidermal growth factor and
20 ng ml–1 human basic ﬁbroblast growth factor-2 (both from Peprotech,
Hamburg, Germany). NSC were cultured at 37 °C under 5% CO2/95% air
and 90% humidity. Medium was replaced every third day. NSC-generated
neurospheres were passaged every ﬁfth day according to the following
protocol: neurospheres were ﬁrst incubated in AccuMax (PAA, Hamburg,
Germany) for 4 min at 37 °C and mechanically triturated with a ﬁre-
polished Pasteur pipette. New NSC cultures were prepared at a density of
40 cells μl–1 in NSC medium and supplemented with 20 ng ml–1 human
epidermal growth factor and 20 ng ml–1 human basic ﬁbroblast growth
factor-2. Tertiary neurospheres were used for all experiments.
Neurosphere growth assay
Tertiary neurospheres were dissociated into single cells and seeded with a
density of 800 cells per well into 96-well suspension culture plates (Greiner
bio-one, Frickenhausen, Germany), containing 200 μl of NSC medium
supplemented with 5 ng ml–1 human epidermal growth factor and
5 ng ml–1 human basic ﬁbroblast growth factor-2. Cells were immediately
treated either with 1IU ml–1 EPO or solvent control, both diluted with PBS,
and cultured for 144 h at 37 °C under 5% CO2/95% air and 90% humidity
without changing the medium. After 144 h, all wells were analyzed for
neurosphere growth: total number of neurospheres per well was counted
for each well and every neurosphere was photographed using an Olympus
IX70 inverse microscope (Olympus, Münster, Germany) and the AnalySIS
software (Soft Imaging System GmbH, Münster, Germany). Sphere
diameter was measured using ImageJ (http://imagej.nih.gov/ij/).
NSC cell death assay, TuJ1 and GFAP staining
For the NSC cell death assay, tertiary neurospheres were dissociated into
single cells as described above and plated at a density of 25 000 cells on
poly-D-lysine (PDL) (Sigma-Aldrich) coated glass coverslips (Paul Marienfeld
GmbH & Co. KG, Lauda-Königshofen, Germany) in four-well plates (Nunc/
Thermo Scientiﬁc, Langenselbold, Germany). NSC were cultured in
minimum essential medium, supplemented with 2% B27, 0.22% sodium
bicarbonate, 1% sodium pyruvate (all from Invitrogen), 1% penicillin/
streptomycin, 2 mM L-glutamine (PAA, Cölbe, Germany) and 0.6% glucose
(Sigma-Aldrich). Cultures received 1IU ml–1 EPO or solvent control, both
diluted with PBS, for 24 h at 37 °C under 5% CO2/95% air and 90%
humidity. After 24 h, NSC cultures were treated with Trypan blue (Sigma-
Aldrich) and vital and dead cells were counted for ﬁve randomly chosen
ﬁelds on each coverslip. For each NSC culture and condition, ﬁve coverslips
were analyzed. For TuJ1 and GFAP staining, NSC were differentiated in
minimum essential medium on PDL-coated glass coverslips in 24-well
plates (Greiner bio-one) in the presence of 1 IU ml–1 EPO or solvent control.
Cells were seeded with a density of 50 000 cells per coverslip. After 96 h,
cells were ﬁxed in 4% PFA in PBS (Sigma-Aldrich) and stained with a
mouse-anti-TuJ1 (1:500, Sigma-Aldrich) or mouse-anti-GFAP (1:1000,
Novocastra, Newcastle Upon Tyne, UK) primary and a goat anti-mouse-
Cy3 secondary antibody (1:1000, Dianova). In addition, cell nuclei were
counterstained with DAPI. For each NSC culture and staining, photos from
eight coverslips (six randomly chosen ﬁelds per coverslip) were taken using
an Axiophot 2 ﬂuorescence microscope (Zeiss, Jena, Germany) with a Spot
Insight camera (Visitron Systems, Puchheim, Germany). From each photo
taken, the number of living and dead (DAPI) as well as TuJ1 or GFAP-
positive cells were counted.
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Knock-down of miR124
Tertiary neurospheres were dissociated into single cells as described
above. NSC were transfected with either the FAM-labeled miRCURY LNA
miR124 inhibitor or the FAM-labeled miRCURY LNA control oligonucleotide
(Exiqon, Skelstedet, Denmark) using the Amaxa mouse neural stem cell
nucleofector kit (Lonza, Cologne, Germany) according to the manufac-
turer's instructions. Both LNA oligonucleotides were used at a concentra-
tion of 60 mM. A neurosphere growth assay was performed 96 h after
transfection as described above with the following change: 2000
transfected cells per well were plated to compensate for the increased
cell death because of the transfection procedure. Cells were treated with
1 IU ml–1 EPO or solvent control (six replicates per condition).
Primary hippocampal neuronal culture E17 (E17-HCC)
Hippocampal cultures from mice at embryonic day 17 (E17) were prepared
as described previously.7 The removal of the meninges and dissection of
the hippocampi was done in Hank’s balanced salt solution (Invitrogen)
supplemented with penicillin/streptomycin (PAA Laboratories GmbH,
Pasching, Austria) and HEPES (Invitrogen). The hippocampi were trypsi-
nized and mechanically triturated with a ﬁre-polished Pasteur pipette. Cells
were seeded on PDL-coated six-well plates for RNA isolation with a density
of 170 000 cells per well. For immunocytochemistry, 25 000 cells were
seeded on PDL-coated coverslips. Neurons were cultured in minimum
essential medium/B27 medium (Invitrogen) supplemented with sodium
bicarbonate, sodium pyruvate, L-glutamine, penicillin, streptomycin and
0.6% glucose. Cultures were incubated at 37 °C under 7.5% CO2/92.5% air
and 90% humidity. To analyze the basal EPOR expression, total RNA was
isolated 0.3 h and 24h after seeding. In all other experiments, cells were
treated with 0.3 IU ml–1 EPO or solvent control 0.3 h after seeding. This
time point is declared as time point 0. RNA was isolated at 0.25, 0.5, 1, 3, 6,
12 and 24 h after treatment. The immunocytochemical analysis was
performed after 6 h, 12 h, 24 h, and at day 8 (d8).
Immunocytochemistry
After 6, 12 and 24 h in culture, cells grown on coverslips were stained for
Dcx or GFAP to analyze the culture composition and double-stained for
Dcx and MAP2 to determine the differentiation ratio. Cells were ﬁxed with
4% paraformaldehyde for 20 min, permeabilized and blocked in 0.2%
Triton-X-100 with 10% NHS in PBS for 20 min. Cells were incubated with
goat anti-Dcx (1:200, Santa Cruz Biotechnologies) or mouse anti-GFAP
(1:500, Novocastra, Newcastle Upon Tyne, UK) in 0.02% Triton-X-100 with
1% NHS at 4 °C overnight, followed by the rabbit anti-goat-Cy2 secondary
antibody or goat anti-mouse-Cy2 secondary antibody (1:1000, Dianova) at
RT. Afterward, coverslips were dried and mounted with ﬂuorescence
mounting medium (Vector Laboratories) containing DAPI. For double
staining, goat anti-Dcx (1:1000, Santa Cruz Biotechnologies) and primary
labeled mouse anti-MAP2 Alexa Fluor 488 antibody (1:2000, Chemicon)
were used to colocalize Dcx with MAP2 expression. At d8, neurons were
quadruple stained for Dcx, MAP2, SynI and SytI. Cells were ﬁrst stimulated
for 10 s with high K+-base solution (70 mM KCl, 140 mM NaCl, 10 mM HEPES,
10 mM glucose, 4 mM MgCl2, 4 mM CaCl2) in presence of rabbit anti-
synaptotagminluminal (1:50, SYSY) and then transferred into low K
+-base
solution (2.4 mM KCl) in presence of the same antibody for 30 s at 37 °C.
After 2-min washing, cells were ﬁxed with 3% paraformaldehyde and 2%
acrolein in PBS for 20 min at RT. Cells were permeabilized and blocked in
0.2% Triton-X-100 with 10% NHS in PBS for 20 min and incubated with
goat anti-Dcx (1:4000, Santa Cruz Biotechnologies) and mouse anti-
synapsin I (1:4000, SYSY) at 4 °C overnight. The next day, cells were
incubated with ﬂuorescently labeled secondary antibodies (1:1000 Alexa
Fluor 546 donkey anti-mouse, 1:500 Alexa Fluor 594 donkey anti-rabbit,
1:1000 Alexa Fluor 633 donkey anti-goat; Invitrogen) for 1 h at RT. Finally,
cells were incubated with primary labeled mouse anti-MAP2 Alexa Fluor
488 antibody (1:2000, Chemicon) at 4 °C overnight. Before mounting
with Aqua Poly/Mount (Polysciences), cells were stained with DAPI
(0.125 μg ml–1, 406 nm; Sigma-Aldrich).
Fluorescent microscopy counting
For analyzing cell number and cell death, the DAPI-stained cells were
counted by using upright light microscope (Axiophot, Zeiss) in two
categories. Cells with homogenous oval nuclei were counted representing
normal living cells. Cells showing a condensed chromatin formation or
fragmented nuclear bodies were considered as apoptotic cells. The number
of apoptotic cells is divided by the total number of DAPI-positive cells to
obtain the percentage of cell death. To estimate culture composition, four
visual ﬁelds of Dcx+ or GFAP+ cells were counted and normalized to DAPI.
Confocal microscopy and analysis
Images were obtained using an inverted confocal laser scanning
microscope (Leica TCS SP2-AOBS; Mannheim, Germany) equipped with
an UV-diode (405 nm), argon (458, 476, 488, 514 nm), DPSS (561 nm) and 2
He–Ne laser (594, 633 nm). Pictures were taken with a 63x Plan-Apo, 1.4NA
oil immersion objective.
Double stain. Images for 6, 12 and 24 h were taken with a line average of
4. Acquisition settings were held constant across recordings within each
experiment. For the intensity-based comparison of Dcx and MAP2, the free
available software Fiji (http://ﬁji.sc/Fiji) was used. Brieﬂy, the 8-bit pictures
were converted into 32-bit pictures, a Gaussian ﬁlter with sigma=232 nm
was applied, the background was subtracted, the lower threshold was set
to 7 and the upper threshold was set to 250. Integrated density of Dcx and
MAP2 was measured and ratio taken.
Quadruple stain. Using sequential image recording with ﬁxed emission
windows and applying a blind source separation technique, we unmixed
the ﬂuorescence contributions of four different ﬂuorescent dyes (Dcx-Alexa
Fluor 633, MAP2 Alexa Fluor 488, SytI-Alexa Fluor 594, SynI-Alexa Fluor
546). Twelve-bit images for d8 were taken with a zoom factor 2.5, line
average 4 and an accumulation of three scans. Detector gain of 500 was
used for all photomultiplier tubes, offset and laser intensity percentages
were held constant across images within each experiment. The choice of
ﬂuorochromes and emission windows (Figure 6a) was optimized for the
subsequent nonnegative tensor factorization decomposition, which further
took available lasers of our imaging setup into account. Images were
acquired sequentially, whereas emission windows were kept ﬁxed. The
images were spectrally decomposed using the nonnegative tensor
factorization algorithm described previously43 with minor modiﬁcations.
The nonnegative tensor factorization algorithm was initialized with spectra
as determined by single stained samples. The spectrum of Alexa Fluor 633
(Dcx) was kept ﬁxed during the decomposition. The nonnegative tensor
factorization algorithm was coded in Python; the source code is available on
request. Further data processing was also done with custom written Python
scripts. Using the unmixed images, we determined the total ﬂuorescence
intensity of Dcx and MAP2 in the area above a threshold (250 in units of
photomultiplier count). To detect synaptic buttons in SynI and SytI stains, we
applied a custom-made feature detection algorithm to the images. Images
where smoothed using a Gaussian ﬁlter with sigma=186nm, Laplace ﬁltered
and thresholded to isolate small maxima in ﬂuorescence intensity
corresponding to synaptic buttons. To increase the signal to noise ratio,
we considered only buttons that have integrated ﬂuorescence intensity
47000. Having detected the putative synaptic buttons, we investigated the
morphology of the buttons positive for SynI, SytI, and those buttons positive
for both SynI and SytI. Analysis scripts are available on request.
Protein extraction
Tissues. Protein extraction and analysis was done as described
previously.44 Mice were decapitated; the hippocampi were taken out,
immediately frozen on dry ice and stored at –80°C. For the analysis of
myelin and control proteins, samples were homogenized in lysis buffer
(50 mM Tris HCl (pH 8.3), 150 mM NaCl, 40 mM NaF, 5 mM EDTA, 5 mM EGTA,
1 mM Na3VO4, 1% Igepal, 0.1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate) also containing 1 mM phenylmethysulfonylﬂuoride, 10 μg ml–1
aprotinin and 10 μg ml–1 leupeptin. The tissue lysates were freeze-thawed
four times and homogenized by pulling through a 1 ml syringe 10 times
and centrifuged at 12 000 r.p.m. for 45 min. To estimate the phosphoryla-
tion of pMAPK/MAPK, total protein was extracted from cultures by using
PhosphoSafe (Merck) according to the manufacturer’s instructions.
Neurosphere suspension cultures. Tertiary neurospheres were dissociated
into single cells as described before and suspension cultures were
prepared with a density of 40 000 cells per suspension culture ﬂask. NSC
were cultured 24 h in NSC medium supplemented with 5 ng ml–1 human
epidermal growth factor and human basic ﬁbroblast growth factor-2 at
37 °C under 5% CO2/95% air and 90% humidity. After 24 h, 1 IU ml
–1 EPO
or PBS was added to the suspension culture and total cell protein was
isolated 10 min after treatment.
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Neurosphere differentiation cultures. Single NSC were plated on six-well
plates (Nunc/Thermo Scientiﬁc), coated with PDL at a density of 170 000
cells per well in minimum essential medium. NSC were allowed to adhere
to the surface for 0.3 h before 1 IU ml–1 EPO or PBS was added and total
cell protein was isolated after 10 min.
E17 hippocampal neuronal cultures. Cells were seeded on PDL-coated
six-well plates with a density of 170 000 cells per well. Cells were treated
with 0.3 IU ml–1 EPO or placebo at 0.3 h or 24 h after seeding and protein
was isolated after 10min.
Immunoblot analysis
Supernatant from cells or tissue (10 μl) were used for determination of
total protein by the Lowry method. The remaining supernatant was mixed
with three volumes of Laemmli buffer (250 mM Tris HCL (pH 8.3), 8%
sodium dodecyl sulfate, 40% glycerol, 20% 2-mercaptoethanol, 0.04%
pyronin Y) boiled for 5–10min at 95˚C and frozen at − 80 °C until blotting.
In all, 10–20 μg protein were run on NuPAGE 4-12% Bis-Tris Gel (Invitrogen)
for 1h at 180 V and transferred to a nitrocellulose membrane for 90 min at
30 V. After blocking with 5% milk in Tween20-Tris-buffered saline at RT for
1h, membranes were incubated with primary antibodies: mouse anti-
pMAPK, rabbit anti-MAPK, mouse anti-CNPase (all 1:1000, Sigma-Aldrich),
rabbit anti-MBP (1:5000, Dako, Carpinteria, CA, USA) and mouse anti-
GAPDH (1:5000, Assay Designs, Ann Arbor, MI, USA), rabbit anti-TOM20
(1:2000, Santa Cruz Biotechnologies), mouse anti-GAD67 (1:5000, SYSY),
mouse anti-Grp75 (1:2000, Assay Designs), rabbit anti-TrkB (1:200, Upstate
Biotechnology, Lake Placid, NY, USA), rabbit anti-Sox9 (1:2000, Millipore,
Billerica, MA, USA), rabbit anti-actin (1:2000, Sigma-Aldrich). Immuno-
reactive bands were visualized by using secondary antibodies coupled to
horseradish peroxidise (1:2000, Sigma-Aldrich) by enhanced chemilumi-
nescence (Immobilon Western, Millipore). Densitometrical analysis of
protein bands was performed using ImageJ software. Proteins were either
normalized to GAPDH (CNPase, MBP, TOM20, GAD67, Grp75, TrkB) or actin
(Sox9).
Isolation of total RNA and quantitative real-time RT-PCR (qPCR)
Tissue or cells were homogenized in Trizol or Quiazol. Total RNA was
isolated by using the miRNeasy Mini Kit (Qiagen, Hilden, Germany).
mRNA. First-strand complementary DNA was generated from total RNA
using N9 random and Oligo(dT) 18 primers. The relative concentrations of
mRNAs of interest in different complementary DNA samples were
measured out of three replicates using the threshold cycle method (delta
Ct) for each dilution and were normalized to levels of beta-actin RNA.
Reactions were performed using SYBR green PCR master mix (ABgene,
Foster City, CA, USA) according to the protocol of the manufacturer.
Cycling was done for 2 min at 50 °C, followed by denaturation at 95 °C for
10 min. The ampliﬁcation was carried out by 45 cycles of 95 °C for 15 s and
60 °C for 60 s. The speciﬁcity of each primer pair was controlled with a
melting curve analysis. For qPCR, we used the following primers: mouse
Dcx (NM_001110222.1) fwd: 5′-CCTTGGATGAGAATGAATGC-3′, rev: 5′-TGA
GTCAGCTGGAGACTTGC-3′; mouse EPOR (NM_010149.2) fwd: 5′-CCTCA
TCTCGTTGTTGCTGA-3′, rev: 5′-CAGGCCAGATCTTCTGCTG-3′; mouse GFAP
(NM_010277.2) fwd: 5′-ACAGACTTTCTCCAACCTCCAG-3′, rev: 5′-CCTTCTG
ACACGGATTTGGT-3′; mouse MAP2 (NM_ 001039934) fwd: 5′-AAGCACT
GATTGGGAAGCACTC-3′, rev: 5′-CGTCGGCCATCTTTCAGATCTC-3′; mouse
ND1 (NM_010894) fwd 5′-CGCAGAAGGCAAGGTGTC-3′, rev 5′-TTTGGTCAT
GTTTCCACTTCC-3′; mouse S100B (NM_009115) fwd: 5′-AACAACGAGCT
CTCTCACTTCC-3′, rev: 5′-CTCCATCACTTTGTCCACCA-3′; mouse Sox9 (NM_
011448.3) fwd: 5′-CAAGCGGAGGCCGAAGA-3′, rev: 5′-CAGCTTGCACGTC
GGTTT-3′, mouse beta-actin (NM_007393.3) fwd: 5′-CTTCCTCCCTGGA
GAAGAGC-3′, rev: 5′-ATGCCACAGGATTCCATACC-3′.
miR124. First-strand complementary DNA synthesis and reactions were
generated from total RNA using the TaqMan MicroRNA RT Kit, TaqMan
MicroRNA Assay for hsa-miR124, TaqMan MicroRNA Assay for sno-RNA142
as a housekeeper and TaqMan 2x Universal PCR Master Mix (ABgene)
according to the protocol of the manufacturer. Cycling was done with
10-min denaturation at 95 °C and ampliﬁcation for 40 cycles at 95 °C for
15 s and 60 °C for 60 s.
Statistical analyses
Data are expressed as mean± s.e.m. All data sets were normally distributed
as ascertained with the Kolmogorov–Smirnov test. Statistical analysis was
performed using two-tailed Student’s t-tests for all in vivo and in vitro data.
One-tailed Student’s t-tests (stated in the Supplementary Figure legend)
were performed whenever experiments were conﬁrmatory or clearly
hypothesis driven. Variances were overall similar between compared
groups. Touch-screen visual discrimination data were analyzed by means
of Kaplan–Meier survival analysis and log ranked Mantel–Cox test. Data
plotting and statistical analysis were done using GraphPad Prism 5
(GraphPad Software, San Diego, CA, USA). Statistical differences were
considered to be signiﬁcant when Po0.05 (*Po0.05, **Po0.01,
***Po0.001, ****Po0.0001). Sample size estimates were based on exten-
sive experience with similar experiments; expected effect sizes (Cohen´s d
see, for example, Cohen45) were according to these previous data strong
(d 4 1; see for example, Sargin et al.44). Considering all the data, we
furthermore performed power analyses to show adequate sample size
according to the observed effect sizes of the experiments (software
G*Power Version 3.1.7, Düsseldorf, Germany). The adequate power (1–β-
error) was deﬁned as ≥ 80% and the α-error as 5%. Overall, adequate
sample sizes led to observed effect sizes (1.23–6.90) agreeing with the
estimates from previous experiments (strong; d 41). Examples of key
experiments: analysis of pyramidal neurons in CA1 in the ﬁrst cohort of
mice (Figure 1b; observed effect size d= 1.97). Analysis of pyramidal
neurons in the ﬁrst cohort of mice in CA3 (Figure 1b; observed d= 1.23).
Analysis of the coefﬁcient of variation of the 15N/14N ratio in the neuronal
nuclei in CA1 (Figure 3l; observed d= 6.90). Analysis of MBP expression in
the hippocampus (Figures 2c and d; observed d =1.45). Analysis of the
percentage of CC-1+/GFP+ within the pool of GFP+ cells in the
hippocampus of NG2-Cre-ERT2:R26R-td-tomato-mEGFP mice (Figure 2l;
observed d= 1.86).
RESULTS
EPO administration to young mice increases neuron numbers in
CA1 and CA3
We applied our EPO treatment protocol known to increase long-
term potentiation and to improve memory7 (experimental design;
Figure 1a). Stereological quantiﬁcation of pyramidal neurons
bilaterally in CA1/CA3 of 8-week-old mice, that is, 1 week after
3 weeks of EPO (5000 IU kg–1 every other day) or placebo injections,
revealed a ~20% increase in mature neurons upon EPO (Figures 1b
and c; Supplementary Figure 1, Supplementary Table 1). This
increase was determined in two independent experiments on
different mouse cohorts. To conﬁrm the augmented pyramidal
neuron numbers, we additionally performed anti-CTIP2 staining.
CTIP2 is a transcriptional regulatory protein46 that speciﬁcally labels
pyramidal neurons in CA1. Indeed, the number of CTIP2+ cells in
CA1 of the EPO-treated group was ~ 22% higher compared with the
placebo group (Figures 1d and e). Importantly, this increase is also
reﬂected by a larger hippocampal volume in MRI in 15-week-old
mice where treatment was started at 11 (instead of 4) weeks of age
(Figure 1f). Total brain volume and body weight of EPO-treated
mice did not differ from placebo (data not shown).
Higher neuron numbers upon EPO are not explained by increased
proliferation or decreased apoptosis
To elucidate the elevated neuron numbers upon EPO in CA1/CA3,
we searched for evidence of increased proliferation or reduced
apoptosis. Surprisingly, we observed the opposite: BrdU+ cells
were diminished (Figure 1g) and apoptotic cells raised (Figure 1h).
Double staining with BrdU and NeuN, a marker of mature neurons,
showed comparable numbers in EPO and placebo mice (Figures 1i
and j). At earlier time points, for example, at 1 week of EPO
treatment, neither proliferation nor apoptosis were altered (data not
shown). In addition, staining for the cell cycle marker Ki67 in whole
hippocampus at 1 week of EPO/placebo injections did not reveal
any differences in Ki67+ cells between treatment groups (224± 34
versus 221±25; P=0.96), supporting that there is no increased DNA
replication in this brain region upon EPO administration.
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Figure 2. Erythropoietin (EPO) effects on oligodendrocytes and myelination. All data are based on bilateral counting. (a) Number of mature
oligodendrocytes with cytoplasmic Olig1 expression in CA1 and CA3 at w4 (placebo n= 8 and EPO n= 10). (b) Olig1+ cells visualized by 3,3’-
diaminobenzidine (DAB) staining. (c) Densitometrical quantiﬁcation of myelin proteins (housekeeping gene GAPDH) extracted from
hippocampal tissue (n= 10 for all proteins and groups except n= 8 for placebo of MBP and CNPase). (d) Sample western blots. (e) Number of
5’-bromo-deoxyuridine (BrdU) and cytoplasmic Olig1 double-positive cells in CA1 and CA3 at w4 (n= 5 for both groups). (f) Illustration of BrdU
and Olig1 colocalization. (g) Number of platelet-derived growth factor receptor α+ (PDGFRα+) OPC at 72 h after start of EPO/placebo
treatment (n= 10 for both groups). (h) PDGFRα+ cells visualized by DAB staining. (i) Number of PDGFRα+ OPC at w4 after start of EPO/placebo
treatment (placebo n= 8 and EPO n= 10). (j) Left hippocampus of NG2-Cre-ERT2:R26R-td-tomato-mEGFP mice at w4 (postnatal day 56),
stained for CC-1, green ﬂuorescent protein (GFP) and 4,6-diamidino-2-phenylindole (DAPI); CC, corpus callosum; PL, pyramidal layer. (k)
Magniﬁcation of the white square area denoted in j, showing a CC-1+/GFP+/DAPI+ cell in all 3 dimensions (xy, xz and yz). (l) CC-1+/GFP+ cells
expressed as percentage of total NG2 (GFP+) cells at w4 (n= 5 for both groups). (m) CC-1+ cells at w4 (n= 5 for both groups). (n) Hippocampus
of NG2-Cre-ERT2:R26R-td-tomato-mEGFP mice at postnatal day 31, showing co-labeling for NG2 and EPOR. HC, total hippocampus; All bar
graphs shown as mean± s.e.m.; all analyses unpaired, two-tailed t-tests, except for subpanel m one-tailed t-test; *Po0.05, **Po0.01,
***Po0.001.
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Reduction of neuronal precursor cells as an early response to EPO
The considerable increase in neurons upon EPO could be due to
an accelerated differentiation of neuronal progenitors. In that
case, staining for immature markers would yield a respective
reduction in number already at early time points. Indeed, cells
stained for the transcription factor Pax6 were decreased in
CA1/CA3 at 72 h after EPO treatment initiation (Figures 1k–m).
Also, the reduction under EPO of doublecortin-positive (Dcx+),
that is, still immature neurons, signiﬁcant in CA3 at 4 weeks, is
compatible with accelerated differentiation (Figures 1n and o). In
line with this observation, a Dcx mRNA decrease of about 25%
was measured by qPCR in hippocampal tissue of EPO versus
placebo-treated mice as early as 6 h after the ﬁrst EPO injection
(mean± s.e.m.; 247 ± 13 versus 184 ± 18; original values x105;
P= 0.012; n= 8 per group).
Increase in neuron numbers by EPO is paralleled by increase in
oligodendrocytes and myelin proteins
Many hippocampal pyramidal neurons have myelinated axons,
and we wondered whether more neurons are associated with
more oligodendrocytes. Indeed, numbers of oligodendrocyte
lineage cells with cytoplasmic expression of Olig1 were on
average 420% increased in CA1/CA3 at week 4 following
EPO (Figures 2a and b), as were myelin-associated proteins,
Golli33, MBP and CNPase (Figures 2c and d). Control proteins
(GAD67, Grp75, Tom20 and TrkB) were all unchanged (data not
shown). Double staining for BrdU and Olig1 revealed similar
numbers in both treatment groups (Figures 2e and f). Consistent
with stimulated differentiation of preexisting OPC by EPO, a
transient reduction in PDGFRα+ cells was observed at 72h
(Figures 2g and h). This reduction was no longer visible at 4 weeks
(Figure 2i).
OPC can differentiate into oligodendrocytes without dividing.26
We repeated the EPO experiment (Figure 1a) in mice,
expressing tamoxifen-inducible Cre-ERT2 under control of the
endogenous NG2 locus.34 Crossing this line with R26R-td-tomato-
mEGFP(mT/mG),35 mice allowed OPC cell fate mapping. In
tamoxifen-pretreated mice (two injections on postnatal days 26
and 27, inducing reporter expression in ~ 60% of hippocampal
OPC), EPO increased GFP+/CC-1+ and total CC-1+ oligodendro-
cytes at week 4 (Figures 2j–m). Supporting a direct EPO effect
on OPC, endogenously labeled cells express EPOR (Figure 2n;
Supplementary Figures 2A and B). Moreover, cultured OPC
produce rising EPOR mRNA levels over time, parallel to myelin
gene induction, whereas progenitor-speciﬁc transcripts decrease
(Supplementary Figure 2C).
Elevated neuronal numbers correlate with elevated 15N-leucine
incorporation
Our data on preexisting OPC that differentiate under EPO, led us
to search for analogous effects in the neuronal lineage.
Unfortunately, speciﬁc molecular markers for preexisting neuronal
progenitors do not exist at present and thus, there is no
corresponding neuronal Cre-ERT2 mouse line available. We
therefore searched for alternative ways to explain how so many
(~20%) newly differentiated neurons appear upon EPO without
prior local cell division. We used multi-isotope imaging mass
spectrometry, NanoSIMS,41 to identify pyramidal neurons with
higher than average 15N-leucine incorporation. In absence of
proliferation markers, this would be indirect evidence for induced
protein synthesis, necessarily associated with the differentiation
and physical growth of large pyramidal neurons from inconspic-
uous precursors (Figures 3a–i).
When we compared the 15N/14N ratio in EdU-/NeuN+ pyramidal
neurons at week 4 (Figure 1a), this ratio clearly scattered toward
higher values upon EPO (Figures 3f and g), indicative of a
pronounced increase in newly synthesized protein in a sub-
population of pyramidal neurons. Indeed, neurons with higher
15N-leucine-incorporation upon EPO amounted to ~ 20% in CA1, in
agreement with the increased cell number detected by stereology
(cresyl violet) and by CTIP2 staining. The coefﬁcient of variation of
the15N/14N ratio was augmented in neuronal nuclei and cytoplasm
(Figures 3h and i).
Effect of EPO on classical neurogenic regions
Our results do not support newly formed neurons from mitotic
(BrdU incorporating) progenitors as a source of the increased
numbers in CA1/CA3. However, 1 week after EPO treatment start,
also the 'classical' adult neurogenesis areas showed a response.
We found an increase under EPO in BrdU+ cells in SVZ and a
similar tendency in DG, in both without altered apoptosis
(Supplementary Figures 3A and B). The rise in Dcx+ neurons in
DG is compatible with stimulated differentiation under EPO also
in this niche (Supplementary Figure 3C). At week 4, in contrast,
we found a reduction in BrdU+ cells in DG/SVZ, likely as a
consequence of temporary depletion of progenitors or negative
feedback on neurogenesis (Supplementary Figure 3D). We also
noted increased apoptosis (Supplementary Figure 3E), potentially
because of abnormal crowding of maturing neurons, comparable
numbers of Dcx+ cells at week 4 (Supplementary Figure 3f), and
more BrdU/NeuN double-labeled neurons upon EPO (Supple-
mentary Figures 3G–I). These data may suggest that EPO
transiently stimulates neuronal precursor proliferation in neuro-
genesis areas. This stimulation, however, is—according to our
working model—probably indirect, that is, a consequence of EPO-
induced precursor differentiation (and thus transient depletion)
rather than a direct EPO effect, as supported by our in vitro
experiments (see below).
Persistence of increased neuron numbers under cognitive
challenge
Next, an experiment was designed to explore the old neurologists’
rule, ‘use-it-or-lose-it’. Starting at week 4 (time point 0 in Figure 1a),
mice were for 22 weeks either exposed to long-term standard
housing without stimulation or to regular cognitive challenge
using the touch-screen paradigm. This paradigm, requiring
hippocampal functions,47,48 allows assessment of visual discrimina-
tion learning over long time periods. EPO-treated mice
needed less time to ﬁnish the touch-screen task (Figure 4a).
Mice that had completed the task continued with regular
touch-screen performance to remain cognitively demanded until
6 months of age. At this time point, EPO-treated mice without
challenge revealed only marginally elevated neuron numbers
in CA3 (Figure 4b), whereas continuously challenged mice had
retained their increased neuron counts in CA1/CA3 (Figure 4c).
Independent of EPO or placebo treatment, cognitively
challenged mice had higher pyramidal neuron numbers
altogether. These data show that enhanced pyramidal neuron
numbers induced by EPO in young mice are maintained under
conditions of ongoing cognitive challenge but not in its absence:
‘Use-it-or-lose-it’.
EPO reduces proliferating neurosphere diameter and number
Based on our in vivo ﬁndings, we wondered whether—similar to
the hematopoietic system—EPO may drive differentiation rather
than directly stimulate proliferation. Dissociated tertiary neuro-
spheres from E14 forebrain cultures (Supplementary Figure 4A)
were grown in suspension clusters with FGF-2/EGF.49 Under these
conditions, neurospheres sustain mainly symmetrically dividing
NSC.50 As prerequisite for testing the EPO inﬂuence on these
cultures, EPOR mRNA expression was conﬁrmed by qPCR and
EPOR function by MAPK activation3 (Supplementary Figure 4B).
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After 144h of EPO exposure, a decrease in total number and
average diameter of neurospheres substantiated an inhibitory EPO
effect on NSC proliferation (Figures 5a–c).
Neurospheres respond to EPO with accelerated differentiation
Next, dissociated tertiary neurospheres were plated in serum-free
medium and treated with EPO or placebo (Supplementary Figure 4C).
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Figure 3. 15N-leucine incorporation in CA1 pyramidal neurons evaluated by nanoscopic secondary ion mass spectrometry (NanoSIMS).
(a) Overview of the hippocampus showing dense proliferation signals (EdU) in the dentate gyrus. The white square illustrates the EdU signal-
free area in the pyramidal layer, analyzed by NanoSIMS. (b and c) Illustration of samples following placebo treatment; (d, e and e’) Illustration
of samples following erythropoietin (EPO) treatment; arrows in e’ point to newly generated neuronal cell mass with high15N/14N ratio; stars in
e’ denote ‘control’ signal in cytoplasmic regions of older neurons. (f and g) Scatter plots of 15N/14N ratios in pyramidal neurons in both
treatment groups. (h and i) Coefﬁcient of variation of 15N/14N ratios in cytoplasm and nuclei of pyramidal neurons (n= 3 for both groups). All
bar graphs are shown as mean± s.e.m.; **Po0.01 (unpaired two-tailed t-test).
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Again, EPOR mRNA expression and functionality were documented
(Supplementary Figure 4D). Sox9, ND1, Dcx, MAP2, GFAP
and S100B were used as differentiation markers on mRNA
level. Compared with placebo (Supplementary Figure 4E;
Supplementary Table 2), Sox9 and ND1 strongly and lastingly
decreased after EPO (Figures 5d and e; Supplementary Table 3), as
did the Dcx/MAP2 ratio, pointing to accelerated neuronal
differentiation (Figure 5f; Supplementary Table 3). The decreased
Sox9 expression was further conﬁrmed on protein level at the 96 h
time point (Figure 5d). GFAP and S100B increased, consistent
with enhanced glial cell numbers paralleling the progression
of neuronal differentiation (Figures 5g and h; Supplementary
Table 3).51 Neurosphere culture composition, cell death and total
cell number are presented in Supplementary Figures 4F–H.
Candidate mediator of EPO effects on neural precursors: miR124
Transcription factor Sox9 and microRNA miR124 are critical for the
homeostasis of differentiation and proliferation in adult neurogen-
esis and functionally connected;52,53 miR124 is increased during
differentiation and elevated in type A neuroblasts after transition
from amplifying type C cells.54 We asked whether changes in
miR124 expression occur also under EPO. Indeed, miR124 was
upregulated in NSC 6 h after EPO addition (Figure 5i). Importantly,
the EPO-mediated reduction in neurosphere numbers was pre-
vented upon miR124 knockdown (Figures 5b and j). Increased
miR124 expression was also found in hippocampus of 28-day-old
mice, 6h after a single i.p. injection of EPO (Figure 5k). Thus, EPO
may act on neurodifferentiation at least partially via miR124.
E17 hippocampal neurons exposed to EPO show rapid shifts in
neural differentiation marker expression
Neurosphere cultures contain mainly early precursor cells, with a
small fraction differentiating into neurons (Supplementary Figure 4F).
Therefore, we studied E17 hippocampal neuron cultures (E17-HCC)
to explore the EPO inﬂuence on cells at a more advanced
differentiation stage (Supplementary Figure 5A). EPOR mRNA
expression and functionality were proven (Supplementary
Figure 5B). Comparable to neurospheres, Sox9 mRNA was
rapidly upregulated upon EPO and declined thereafter
(Supplementary Figures 5C and D; Supplementary Table 5).
ND1 (Supplementary Figure 5E) and Dcx/MAP2 decreased as well
(Supplementary Figure 5F; Supplementary Table 5). Dcx/MAP2
decrease was conﬁrmed on protein level by immunocytochemistry-
based integrated density (Supplementary Figures 5G and H). GFAP
and S100B in E17-HCC responded to EPO with short-lived
decrease (Supplementary Figures 5I and J; Supplementary
Table 5). Culture composition, cell death and total cell number
were unchanged (Supplementary Figures 5K–M).
EPO-induced differentiation provokes earlier maturation of
neurons
To explore effects on synapse maturation, E17-HCC were treated
with EPO/placebo 0.3 h after seeding and analyzed on day 8, when
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Figure 4. Use-it-or-lose-it experiment. (a) Long-term learning curve
in the touch-screen visual discrimination task showing signiﬁcantly
earlier task completion of erythropoietin (EPO)-treated mice
(placebo n= 11 and EPO n= 10, log-rank (Mantel–Cox) test).
(b and c) Pyramidal neuron counts obtained by stereological
counting at 6 months of age (4 months after cessation of
EPO/placebo treatment) in mice without (n= 10 in case of CA1 for
both groups, and n= 9 and n= 10 in case of CA3 for placebo and
EPO groups, respectively) (b) or with (n= 11 for placebo, for EPO
n= 8 and n= 9 in CA1 and CA3, respectively) (c) continuous
cognitive challenge using touch-screen. All bar graphs shown as
mean± s.e.m. (all analyses unpaired one-tailed t-tests).
Figure 5. Erythropoietin (EPO) effects on proliferation and differentiation of E14 forebrain neurospheres and role of miR124; (a-c) Quaternary
E14 forebrain neurospheres cultured under proliferating conditions: histogram showing total number (a) and number by diameter (n= 4 per
group, paired two-tailed t-test) (b) of quaternary neurospheres at 144 h after EPO/placebo (n= 4 per group, paired two-tailed t-test). (c) Phase
contrast image of neurospheres. (d-j) Quaternary E14 forebrain neurospheres cultured under differentiating conditions: (d-h) qPCR/western
blot results of differentiation markers. EPO-induced changes are expressed as % difference from placebo at the respective time point.
Compare Supplementary Table 3. (d) Early neural marker Sox9, shown at mRNA level (0.3 h: n= 5, 24 h: n= 5, 96 h: n= 5, 168 h: n= 6, paired
two-tailed t-test per time point), as well as protein level (n= 3 per group, paired two-tailed t-test per time point) together with a sample
western blot. (e) Early neural marker ND1 (0.3 h: n= 6, 24 h: n= 6, 96 h: n= 5, 168 h: n= 6, paired two-tailed t-test per time point). (f) Dcx/MAP2
ratio (0.3 h: n= 6, 24 h: n= 10, 96 h: n= 9, 168 h: n= 6, paired two-tailed t-test per time point). (g and h) GFAP (0.3 h: n= 7, 24 h: n= 7, 96 h:
n= 6, 168 h: n= 7, paired two-tailed t-test per time point) and S100B (0.3 h: n= 6, 24 h: n= 11, 96 h: n= 9, 168h: n= 6, paired two-tailed t-test
per time point). (i and j) miR124 expression and consequence of miR124 knockdown in proliferating neurospheres: (i) miR124 expression in
proliferating neurospheres at 6h after addition of EPO/placebo (n= 8 per group, paired two-tailed t-test). (j) Neurospheres with diameter
4100 μm at 96h after addition of EPO/placebo to neurospheres transfected with miR124 antisense (AS) or scrambled sense (control) oligos
(n= 4 per group, paired one-tailed t-test). (k) miR124 expression in hippocampus of 28 day-old mice 6h after treatment with EPO/placebo
(n= 8 per group, unpaired one-tailed t-test). All n-numbers given for the in vitro data are derived from biological replicates, that is,
independent cell preparations. All bar graphs are shown as mean± s.e.m.; *Po0.05, **Po0.01, ***Po0.001.
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ﬁrst excitatory synapses are formed.55 As biochemical indicators of
synapse maturation/synaptic activity, we used synaptotagmin I
(SytI) and synapsin I (SynI). Antibodies against the luminal domain
of SytI were used previously to examine the exo-endocytotic
recycling of synaptic vesicles and reﬂect the number of exocytotic
events.56 Cells were quadruply stained (Figure 6a).43 Figure 6b
illustrates the progressed differentiation at d8, with Dcx expres-
sion fading and MAP2 dominating. The EPO effect is again
reﬂected in the decreased Dcx/MAP2 ratio (Figure 6c). We stained
for SynI and SytI (Figures 6d and e) and created masks for both
markers (Figure 6f). Their colocalization indicates active synapses56
(Figure 6f, white spots) whereas SynI single positive puncta refer
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to inactive synapses (Figure 6f, red spots). The size of the
colocalized area (active area, white spots) was taken as a measure
of synaptic activity. Whereas we found no change in the number
of active synapses (data not shown), an increase in mean active
area per spot was detected (Figure 6g), indicating progressed
neuronal maturation under EPO.
DISCUSSION
We report here the unexpected observation that a 3-week
systemic administration of EPO, known to cross the blood–brain
barrier,2,12,57 induced a ~ 20% increase in CA1/CA3 neurons and
oligodendrocytes in young mice. We ruled out local proliferation
of neural precursor cells and antiapoptotic effects of EPO1,2 as
underlying mechanisms. Conversely, we found a decrease in BrdU-
positive and an increase in apoptotic cells, compatible with
depletion of local precursors and death of a subset of newly
generated (supernumerary) neurons. However, the concept of
‘preexisting neuronal precursors’ is at variance with the conven-
tional view of adult neurogenesis, as opposed to preexisting
oligodendrocyte precursors, which are widely accepted.26 We are
certainly aware of open experimental questions that preclude ﬁnal
conclusions at this stage, but we will discuss our data in a ‘working
model’ to help guiding future research. This working model is
novel and, if conﬁrmed by other labs, the underlying concept of
adult neurogenesis without entering cell cycle may be reminiscent
of adult OPC that can also trans-differentiate without proliferation.
Both could be of major signiﬁcance for rapid regenerative
processes in the brain.
For proof-of-concept that the elevated number of oligo-
dendrocytes upon EPO is derived from preexisting OPC, we used
mice expressing an inducible oligodendrocyte lineage marker, the
tamoxifen-inducible Cre-ERT2 gene58 under control of the
endogenous NG2 promoter.34 Indeed, we found increased
numbers of labeled oligodendrocytes at 4 weeks after initiation
of EPO treatment. Unfortunately, speciﬁc molecular markers for
genetically targeting analogous neuronal precursor stages remain
to be deﬁned and Cre-ERT2 tools to be developed. We therefore
used advanced mass spectroscopy, NanoSIMS,41 to support the
possibility that ~ 20% of CA1/CA3 neurons (as detected by
stereology and CTIP2 staining) were newly generated. Intriguingly,
we found exactly this percentage of neurons in CA1 with highly
elevated 15N-leucine incorporation upon EPO in absence of
proliferation markers. This ﬁnding is indeed consistent with
enhanced protein synthesis underlying the growth of newly
differentiated pyramidal neurons from preexisting postmitotic
local precursors. Future studies will have to address whether
similar results can be obtained in other central nervous system
regions.
Complementing the pivotal work of many groups on adult
neurogenesis in distinct regions of the brain, such as DG and SVZ,
for example, see refs 21–25,52,59, our ﬁndings have led us to a
working model, in which we discuss the postnatal delivery of new
functional neurons and oligodendrocytes in the hippocampus
from a pool of local precursors, outside the 'classical' neurogenic
regions. In this working model, migration of precursors from DG/
SVZ to the hippocampus, as induced in disease states, for
example, see refs 60–62, may ultimately replenish this pool.
Interestingly, using a nestin-GFP reporter mouse, a population of
Dcx/MAP2
0.0
0.2
0.4
0.6
*
d8
Placebo
EPO
R
at
io
 in
te
gr
at
ed
 d
en
si
ty
Mean active area
0.20
0.22
0.24
0.26
*
d8
M
ea
n 
ar
ea
 o
ve
rla
p 
(µ
m
2 )
Syn I
Syt I
Syn I
Syt I
* *
Syn I
Syt I
Dcx
MAP2
DAPI
Figure 6. Effects of erythropoietin (EPO) on neuronal differentiation and maturation, determined by mean active area of synapses in E17-HCC.
Neurons (d8) were quadruply stained for differentiation markers Dcx and MAP2 and activity markers Synaptotagmin I (SytI) and Synapsin I
(SynI) (n= 8). Staining was analyzed by confocal microscopy. (a) The protocol includes three sequential scans with ﬁxed emission windows
(orange) with different excitation wave length. Excitation (dashed line) and emission (solid line) spectra are shown for each ﬂuorescent dye,
Alexa Fluor 488 (MAP2, green), Alexa Fluor 546 (SynI, blue), Alexa Fluor 594 (SytI, red) and Alexa Fluor 633 (Dcx, black). 4,6-Diamidino-2-
phenylindole (DAPI) ﬂuorescence was determined using an additional excitation at 406 nm. (b) Unmixed confocal picture showing
differentiation markers Dcx (red), MAP2 (green) and DAPI (blue). (c) Quantiﬁcation of the integrated density of Dcx and MAP2 presented as
ratio (n= 8 per group, paired one-tailed t-test). (d) Unmixed confocal picture showing SytI (green) and SynI (red). (e) Higher magniﬁcation of
the square mark of picture d, showing single stained dots for SytI (green, arrowhead), single stained dots for SynI (red, star) and colocalized
dots (yellow, arrow). (f) Masked images for analyzing the number and area of SytI (green, arrowhead), SynI (red, star) and colocalized (white,
arrow) dots. (g) Quantiﬁcation of the mean overlapping (colocalized) area as mean active area (white spots in f, n= 8 per group, paired two-
tailed t-test). All n-numbers given are derived from biological replicates, that is, independent cell preparations. All bar graphs are shown as
mean± s.e.m.; *Po0.05.
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bipolar cells was identiﬁed in CA1 that did not incorporate BrdU
and was negative for GFAP, S100B and Dcx. These cells were
traced back to the corpus callosum alveus, a region dorsal of
CA1/CA3, where neuronal stem cells have also been extracted
from.63,64
In connection with disease models, EPO treatment was
associated with increased numbers of BrdU+ cells in DG and
SVZ.16,17 This fact and also the timing when BrdU+ cells were
found enhanced are in good agreement with our data. Even the
observation of a decrease in BrdU+ cells in neurogenic areas
at week 4 as described here was similarly noted before, but
understood as lacking long-term effects of EPO on adult
neurogenesis.16 The conclusions drawn by others that EPO
stimulates neuroproliferation, however, are not supported here.
In contrast, we interpret our ﬁndings not (or only to a limited
degree) as direct effects of EPO on neuroproliferation but rather as
feedback signaling of differentiating neurons to proliferating
progenitors. For example, the mere depletion of neuroblasts (by
EPO stimulated differentiation) could release the reported GABA
brake on stem cell proliferation.65,66
In neural stem cells (E14-NSC) and hippocampal cultures
(E17-HCC), we found evidence for EPO-induced differentiation/
maturation rather than proliferation. These ﬁndings are a major
supportive argument for the validity of our working model, and as
such a central part of the present work. Although the cultures
differ in their differentiation state, EPO apparently targets the
same transcription factors, Sox9 and ND1. Similar ﬁndings on
differentiation of secondary NSC were reported previously,17
whereas discrepant results were seen using unphysiologically high
doses, for example, Chen et al.67 Importantly, miR124, known to
regulate Sox952,53 and drive neuronal differentiation at the
expense of proliferation, is shown here to be stimulated by EPO
and mediate its inhibitory effect on neurosphere number/
diameter. Clearly, the increase in miR124 upon EPO in vivo and
in vitro is small but consistent. Notably, the growing literature on
microRNAs in the brain indicates that even relatively small
changes in their levels can have substantial impact on cellular
function.68,69
The presently lacking information on further brain areas, for
example, cortex or cerebellum, female gender, other species or
older age at EPO treatment still limits the generalizability of our
ﬁndings. Nevertheless, our MRI data showing hippocampal
enlargement were obtained from 15-week-old male mice, that
is, from animals where EPO administration had started at 11
(instead of 4) weeks of age. We note that similar volume increases
of hippocampal CA1/CA3 subﬁelds were reported recently by
high-resolution MRI following EPO treatment in human patients.11
This clinical observation is in perfect agreement with our ﬁndings
in healthy young mice and may point to the relevance of EPO for
neurogenesis also in advanced adulthood and across species.
Exploring how EPO acts on cognition, we presumably 'tapped'
into a physiological system of neuronal (re)generation from local
precursors that can be pharmacologically manipulated with
recombinant human EPO. One important explanation why this
novel type of postnatal neurogenesis has escaped detection in the
past is the astonishing ﬁnding that it occurs in absence of mitotic
cell division. Thus, it cannot be captured by incorporation of BrdU,
tritiated thymidine, or retroviral labeling strategies, classical tools
in the ﬁeld.23 The second reason for detecting this type of
neurogenesis by serendipity is that we have enhanced the
underlying transition of resident precursor cells to mature neurons
and oligodendrocytes by EPO. If this type of postnatal neurogen-
esis and gliogenesis is likewise present in untreated mice, it may
also occur at a low rate for continuous on-demand delivery of
neurons, which cannot easily be demonstrated by absolute cell
counts. First support for this hypothesis is the increase in
pyramidal CA1/CA3 neurons upon long-term cognitive challenge,
with and without EPO.
In conclusion, our data provide a working model for the cellular
basis of so far unexplained but consistent clinical ﬁndings that
EPO improves cognition in mouse and man. Speciﬁcally, we note
the possibility that neurons can be generated rapidly, that is,
without entering S-phase, and also outside the 'classical’
neurogenesis areas, that is, from inconspicuous local precursors
that may have been overlooked. A conceptually similar scenario
was proven here for oligodendrocytes, demonstrating that their
adult precursors (NG2 cells)27,29,30 can more efﬁciently differenti-
ate under EPO without proliferation. Functionality of the newly
generated neurons is suggested by enhanced long-term potentia-
tion in Schaffer collateral CA1 synapses7 and by faster learning in
the touch-screen setup as shown here, and of newly generated
oligodendrocytes by enhanced myelin protein expression. Given
these ﬁndings, the upregulation of EPO and EPOR in the
injured brain is intriguing.2,6 But independent of its role in central
nervous system regeneration, our observations add a new layer of
complexity to postnatal neurogenesis.
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